Image default
Greek News

Kodak’s stock triples as company announces pandemic plan to start making pharmaceutical ingredients

The Trump administration’s $765 million loan to the Eastman Kodak Co. for its launch of a business making pharmaceutical ingredients sent shares of the iconic camera company soaring.

Kodak’s stock KODK, rallied more than 200% on Tuesday after the news was announced by the Trump administration. The company emerged from a 2011 bankruptcy in 2013, and its shares tumbled from a 10-year high of $37.20 on Jan. 9, 2014, to a low of $1.55 on March 23 of this year.

“Never again do we want to rely on shipments from China or elsewhere in order to get lifesaving medical supplies,” New York Gov. Andrew Cuomo said in a statement.

Kodak, which is based in Rochester, N.Y., and has a long history of manufacturing chemicals used in photographic film, now plans to support “America’s self-sufficiency in producing the key pharmaceutical ingredients we need to keep our citizens safe,” Kodak’s executive chairman, Jim Continenza, said in a statement.

The Trump administration said the Kodak deal is the first of its kind and uses powers afforded by the Defense Production Act. The administration previously used these powers to demand that Ford Motor Co. F, begin manufacturing respirators and masks and that General Motors Co. GM, make ventilators.

See Also:

The settlement of Europe could be the result of several immigration waves by a single population

Famed Pablo Picasso painting reveals abandoned artwork beneath

It also awarded $354 million to Phlow Corp. in May to start producing active pharmaceutical ingredients, or API, among other chemical ingredients, used in certain essential medications. A spokesperson for Phlow said the company can’t disclose the list of drugs, but it includes treatments for pain and blood pressure that can be used by hospitalized COVID-19 patients. The total contract is worth up to $812 million. Phlow cites a shift toward producing API in China and India as the rationale behind its business model.

But one Wall Street analyst is questioning why these contracts were not awarded to companies like Amneal Pharmaceuticals Inc. AMRX, Mylan MYL, and Teva Pharmaceutical Industries Ltd. TEVA, all of whom have generic-drug manufacturing know-how.

Read more: Marketwatch

Σχετικα αρθρα

Greek debt reduction in absolute numbers begins

admin

Greek hotels fear bankruptcy, survey shows

admin

European Commission approves 1.2 billion euros to support Greek economy

admin

Hellenic Sugar Industry signs lease for two plants to consortium

admin

Athens Stock Exchange rallies at opening with 5.6% rise

admin

Tech Giants Shrug Off COVID-19 Crisis in Q1 (infographic)

admin

500 Spain hotels ‘to close immediately’ after Thomas Cook fall

admin

Turkey’s economy most vulnerable in G20 to COVID-19, Moody’s says

admin

PM Mitsotakis urges investors to choose Greece at CFR event

admin

Government gears up to conclude fourth post-bailout review

admin

Where the EU imports its clothes from (infographic)

admin

The Billion-Dollar Holiday (infographic)

admin

World’s largest car manufacturers by revenue (infographic)

admin

European Commission issues positive report on Greece

admin

Greece sells successfully six-month bond

admin

Cyprus, Malta lead EU ranking of $1.6 trillion assets held offshore!

admin

Greece generates nearly half of its electricity from coal (infographic)

admin

UPD – PM Mitsotakis announces 24 billion package to restart economy

admin